Thompson Rahsaan 4

What Happened

• Rahsaan Thompson, Chief Legal & Compliance (Secretary) of Zevra Therapeutics (ZVRA), reported multiple transactions tied to equity awards and an open‑market sale. On Jan 30, 2026 he sold 4,080 shares in the open market at a weighted average price of $8.83 for total proceeds of $36,010.
• Related to equity awards, the filing shows derivative activity: 11,333 shares were recorded as exercised/converted (acquired) and 11,333 shares were recorded as disposed at $0.00 (derivative), consistent with RSU settlement and shares withheld for taxes. The filing also reports grants on Jan 29, 2026 of 37,500 and 75,000 derivative awards (RSUs and/or option grants) at $0.00.

Key Details

• Dates & prices: Open‑market sale 4,080 shares on 2026-01-30, weighted avg price $8.83 (trades ranged $8.58–$9.04). Exercise/conversion and derivative settlements recorded 2026-01-30; grants dated 2026-01-29. Report filed 2026-02-02.
• Proceeds: Sale reported as $36,010. Some shares from vesting were withheld/disposed at $0.00 (tax withholding/settlement).
• Shares owned after transaction: Not specified in the supplied summary of the Form 4.
• Notable footnotes: F1 = each RSU converts to one share; F2 = 10b5‑1 plan adoption date 3/27/2025 (sale likely under a trading plan); F3 = sale executed in multiple trades; F4/F6 = RSU vesting schedule (one‑third vested/settled on Jan 30, 2026; remaining vest in annual installments); F5 = stock option grant vests over four years.
• Timeliness: Filed on 2026-02-02 for transactions on 2026-01-29/30—appears timely under Form 4 reporting rules.

Context

• This filing combines a routine open‑market sale with award activity. The derivative entries indicate RSUs/options vested and were settled; some of the settled shares were sold in the market while others were withheld/disposed (reported at $0) likely for taxes. The sale was executed under a 10b5‑1 plan (adopted 3/27/2025), which is a pre‑arranged trading plan commonly used to avoid timing questions.
• These types of filings are factual records of insider transactions and do not by themselves indicate the insider’s view of the company’s prospects.